| Similar Articles |
 |
Bio-IT World October 2006 John Russell |
GNS Charts "Unknown" Biology Gene Network Sciences' CEO and colleagues now think they have the right tool to mine the treasure trove of unknown biology hidden in the wealth of accumulating omic data.  |
Bio-IT World September 2006 John Russell |
Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following.  |
Bio-IT World November 12, 2002 Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?  |
Bio-IT World September 2006 John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field.  |
Bio-IT World June 17, 2004 John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine.  |
Bio-IT World Dec 2006/Jan 2007 John Russell |
Setting the Systems Bio Syllabus An interview with David de Graaf about Pfizer's growing comfort with systems biology.  |
Bio-IT World December 15, 2003 Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials.  |
Bio-IT World March 8, 2005 John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.  |
Pharmaceutical Executive September 1, 2005 Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next.  |
CIO October 15, 2001 Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...  |
Bio-IT World September 2006 Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.  |
Bio-IT World September 2005 John Russell |
Labor Pains and Gains Labor Day is the starting gun for the bio-science industry's race through the next year. Here are some up-and-coming items to watch: Transparency... Systems Biology... Crawford and McClellan...  |
Bio-IT World Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc.  |
Pharmaceutical Executive May 1, 2007 Weiner & Hovde |
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks.  |
Bio-IT World November 2006 Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.  |
Bio-IT World January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics.  |
Bio-IT World May 9, 2003 Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development.  |
Pharmaceutical Executive January 1, 2006 Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay?  |
Bio-IT World October 14, 2004 Zachary Zimmerman |
Follow the Pathway to Increased ROI Although this software has been commercially available for only a year, Ingenuity claims nine of the top 10 pharmaceutical companies as customers, including Pfizer, Wyeth, GlaxoSmithKline, and Aventis.  |
Bio-IT World August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc.  |
Pharmaceutical Executive February 1, 2006 Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.  |
Bio-IT World April 15, 2003 Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.  |
Bio-IT World November 12, 2002 James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.  |
Bio-IT World May 19, 2004 John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology.  |
Bio-IT World February 2006 John Russell |
Preventable Vioxx Problems? Pathway analysis tools might have identified Vioxx's problematic off-target activity much earlier. Wondering which modeling approach to use for your project?  |
Bio-IT World November 2006 Kevin Davies |
Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.  |
Bio-IT World December 15, 2004 Kevin Davies |
Into the Valley of Innovation An interview with president and CEO Curt Carlson of research hothouse SRI International on new technology and accelerating drug development.  |
Bio-IT World October 14, 2004 |
Deciphering Genstruct If you divide the systems biology world into two broad camps, wet-lab-focused data generators and in silico model makers, Genstruct is a modeler with a twist.  |
Pharmaceutical Executive June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.  |
Bio-IT World November 2005 Mark D. Uehling |
The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry.  |
Bio-IT World August 18, 2004 Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test.  |
Bio-IT World March 8, 2005 John Russell |
Debating Business Models for Bioinformatics Companies Nailing down a single formula for successfully selling bioinformatics products or services has proven elusive. Harvard Business School tackles informatics' basic question: Where's the money?  |
The Motley Fool October 26, 2010 Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer."  |
Bio-IT World July 14, 2004 Davies & Russell |
The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology.  |
Bio-IT World August 2005 John Russell |
Pfizer's Model of Success Pfizer Global Research & Development began using sophisticated modeling technology and collaboration software to speed its race to a go-no-go decision on a cholesterol-lowering drug project. Killing the project sooner saved up to $2.8 million in costs and six months in delay.  |
Bio-IT World March 2007 John Russell |
In Search of Spring Tired of winter? Here are some signs of spring for systems biology acceptance and a preview of Cambridge Healthtech's June conference, Applying Systems Biology, to whet your appetite for summer: 1. FDA Survey... etc.  |
Bio-IT World Dec 2006/Jan 2007 John Russell |
Novartis' Answer to Harry Potter Imagine a magic wand able to instantly materialize novel, safe, and effective drugs. No such device exists, of course, but Novartis has a distant cousin of sorts: the UltraLink is an immensely powerful text-mining tool and knowledge management platform.  |
Bio-IT World August 13, 2003 Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.  |
Pharmaceutical Executive April 1, 2007 Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.  |
Pharmaceutical Executive July 1, 2012 |
Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?  |
Pharmaceutical Executive June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?  |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies...  |
Bio-IT World July 2005 Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created.  |
Bio-IT World March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.  |
Industrial Physicist Jennifer Ouellette |
Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems  |
Bio-IT World March 2006 John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs.  |
Pharmaceutical Executive January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs  |
Bio-IT World September 16, 2004 Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open  |
Bio-IT World March 8, 2005 Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending.  |
Bio-IT World February 10, 2003 Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering.  |